A CFD-DEM Investigation of Powder Transport and Aerosolization in ELLIPTA® Dry Powder Inhaler

Overview

Journal Powder Technol

Date 2022 Nov 9

PMID 36348745

Authors

Mostafa Sulaiman

Xiaoyu Liu

Sankaran Sundaresan

Affiliations

Soon will be listed here.

Abstract

We have performed Computational Fluid Dynamics-Discrete Element Method (CFD-DEM) simulations of air and particles in a commercial ELLIPTA® inhaler. We simulated the fluidization, deagglomeration and transport of carrier and API particles, with two realistic inhalation profiles that are representative of moderate asthma and very severe COPD patients, and three different mouthpiece designs. In each of the ten cases simulated, we determined the fine particle fraction (FPF) in the stream leaving the mouthpiece, the temporal evolution of the spatial distribution of the particles, the mean air (slip) velocity seen by the carrier particles, and the average numbers and normal impact velocities of carrier-carrier and carrier-wall collisions inside the inhaler. In the cases examined, the air-carrier and carrier-carrier interactions affected the FPF, while the carrier-wall interactions were too infrequent to have a substantial effect. The simulations revealed the benefit of loading both blisters even when only a single medication needs to be delivered.

References

Sommerfeld M, Cui Y, Schmalfuss S . Potential and constraints for the application of CFD combined with Lagrangian particle tracking to dry powder inhalers. Eur J Pharm Sci. 2018; 128:299-324. DOI: 10.1016/j.ejps.2018.12.008. View

Sulaiman M, Liu X, Sundaresan S . Effects of dose loading conditions and device geometry on the transport and aerosolization in dry powder inhalers: A simulation study. Int J Pharm. 2021; 610:121219. PMC: 9619387. DOI: 10.1016/j.ijpharm.2021.121219. View

Prime D, De Backer W, Hamilton M, Cahn A, Preece A, Kelleher D . Effect of Disease Severity in Asthma and Chronic Obstructive Pulmonary Disease on Inhaler-Specific Inhalation Profiles Through the ELLIPTA® Dry Powder Inhaler. J Aerosol Med Pulm Drug Deliv. 2015; 28(6):486-97. PMC: 4685483. DOI: 10.1089/jamp.2015.1224. View

Milenkovic J, Alexopoulos A, Kiparissides C . Flow and particle deposition in the Turbuhaler: a CFD simulation. Int J Pharm. 2013; 448(1):205-13. DOI: 10.1016/j.ijpharm.2013.03.004. View

Yu J, Wong J, Ukkonen A, Kannosto J, Chan H . Effect of Relative Humidity on Bipolar Electrostatic Charge Profiles of dry Powder Aerosols. Pharm Res. 2017; 34(8):1707-1715. DOI: 10.1007/s11095-017-2178-3. View

Zheng Z, Leung S, Gupta R . Flow and Particle Modelling of Dry Powder Inhalers: Methodologies, Recent Development and Emerging Applications. Pharmaceutics. 2021; 13(2). PMC: 7912775. DOI: 10.3390/pharmaceutics13020189. View

Guenette E, Barrett A, Kraus D, Brody R, Harding L, Magee G . Understanding the effect of lactose particle size on the properties of DPI formulations using experimental design. Int J Pharm. 2009; 380(1-2):80-8. DOI: 10.1016/j.ijpharm.2009.07.002. View

de Boer A, Chan H, Price R . A critical view on lactose-based drug formulation and device studies for dry powder inhalation: which are relevant and what interactions to expect?. Adv Drug Deliv Rev. 2011; 64(3):257-74. DOI: 10.1016/j.addr.2011.04.004. View

Zhou Q, Tong Z, Tang P, Citterio M, Yang R, Chan H . Effect of device design on the aerosolization of a carrier-based dry powder inhaler--a case study on Aerolizer(®) Foradile (®). AAPS J. 2013; 15(2):511-22. PMC: 3675743. DOI: 10.1208/s12248-013-9458-6. View

10.

Horvath A, Balashazy I, Tomisa G, Farkas A . Significance of breath-hold time in dry powder aerosol drug therapy of COPD patients. Eur J Pharm Sci. 2017; 104:145-149. DOI: 10.1016/j.ejps.2017.03.047. View

11.

Mitani R, Ohsaki S, Nakamura H, Watano S . Numerical Study on Particle Adhesion in Dry Powder Inhaler Device. Chem Pharm Bull (Tokyo). 2020; 68(8):726-736. DOI: 10.1248/cpb.c20-00106. View

12.

Coates M, Chan H, Fletcher D, Chiou H . Influence of mouthpiece geometry on the aerosol delivery performance of a dry powder inhaler. Pharm Res. 2007; 24(8):1450-6. DOI: 10.1007/s11095-007-9262-z. View

13.

Longest P, Bass K, Dutta R, Rani V, Thomas M, El-Achwah A . Use of computational fluid dynamics deposition modeling in respiratory drug delivery. Expert Opin Drug Deliv. 2018; 16(1):7-26. PMC: 6529297. DOI: 10.1080/17425247.2019.1551875. View

14.

Ngoc N, Chang L, Jia X, Lau R . Experimental investigation of design parameters on dry powder inhaler performance. Int J Pharm. 2013; 457(1):92-100. DOI: 10.1016/j.ijpharm.2013.08.072. View

15.

Liu X, Sulaiman M, Kolehmainen J, Ozel A, Sundaresan S . Particle-based coarse-grained approach for simulating dry powder inhaler. Int J Pharm. 2021; 606:120821. PMC: 10679953. DOI: 10.1016/j.ijpharm.2021.120821. View

16.

Jones M, Hooton J, Dawson M, Ferrie A, Price R . An investigation into the dispersion mechanisms of ternary dry powder inhaler formulations by the quantification of interparticulate forces. Pharm Res. 2007; 25(2):337-48. DOI: 10.1007/s11095-007-9467-1. View

17.

Coates M, Chan H, Fletcher D, Raper J . Influence of air flow on the performance of a dry powder inhaler using computational and experimental analyses. Pharm Res. 2005; 22(9):1445-53. DOI: 10.1007/s11095-005-6155-x. View

18.

Donovan M, Kim S, Raman V, Smyth H . Dry powder inhaler device influence on carrier particle performance. J Pharm Sci. 2011; 101(3):1097-107. DOI: 10.1002/jps.22824. View

19.

Benque B, Khinast J . Estimating inter-patient variability of dispersion in dry powder inhalers using CFD-DEM simulations. Eur J Pharm Sci. 2020; 156:105574. DOI: 10.1016/j.ejps.2020.105574. View

20.

Hamilton M, Leggett R, Pang C, Charles S, Gillett B, Prime D . In Vitro Dosing Performance of the ELLIPTA® Dry Powder Inhaler Using Asthma and COPD Patient Inhalation Profiles Replicated with the Electronic Lung (eLung™). J Aerosol Med Pulm Drug Deliv. 2015; 28(6):498-506. PMC: 4685503. DOI: 10.1089/jamp.2015.1225. View